Zhu et al.’s239 research showed that CAR‐T cells specifically developed to target CD133 have the ability to efficiently eradicate CD133+ CSCs in glioma patients, whether in laboratory settings or under experimental conditions in model organisms. This evidence concerns the gene PROM1 and central nervous system cancer.